Chongqing Asincan Biotech Co.,Ltd. (hereinafter referred to as the "Company") is a drug research and operation company with strong R&D capabilities. The company is committed to becoming an excellent and reliable API manufacturer and supplier; the company mainly focuses on the development and operation of drugs for anemia, especially iron deficiency anemia, and also focuses on medications for middle-aged and elderly diseases and gynecological diseases, including heart Drugs for vascular, diabetes, cancer, endometriosis and uterine fibroids.

　　The company has completed the process research of Delafloxacin Meglumine, Tedizolid Phosphate, Elagolix Sodium, Carfilzomib, Fulvestrant, Palbociclib, Apremilast, Tofacitinib Citrite, Apixaban, Rivaroxaban and Pimavanserin, among which Delafloxacin Meglumine, Tedizolid Phosphate and Elagolix Sodium, Farfilzomib, Fulvestrant and Apremilast are our strong products, and a large number of customers have cooperated with us.

　　The company is developing Ferric carboxymaltose, Ferric maltol, Ferric Citrate, Polysaccharide-Iron Complex, Iron Sucrose, and Roxastat. (Roxadustat) and other anemia drugs, the company will strive to become an expert in iron products.

　　The company is based on the Chinese market, semi-standard and non-standard markets, and appropriately enters the European, American and Japanese markets; the company adopts flexible, mutually beneficial, common development, and long-term cooperation models. There are full-time employees in India responsible for marketing, and close partners in Bangladesh, Pakistan, Europe, South America, North America, Africa and the Middle East. At the same time, we welcome more partners to cooperate with our company.

　　The company's main business includes:

　　1. Supply of APIs and intermediates

　　2. Contract research, technology transfer and services for APIs and preparations, including process research, quality research, consistency evaluation, etc.

　　3. Customized production

　　4. Sales service